American CryoStem Posts Letter to Shareholders
January 06 2014 - 1:45PM
John Arnone, Chairman and CEO of American CryoStem Corporation
(OTCQB:CRYO), a leading strategic developer, marketer and global
licensor of patented adipose tissue-based cellular technologies for
the Regenerative and Personalized Medicine industries, today issued
a formal update in the form of a Letter to Shareholders posted to
the Company's web site at
www.americancryosystem.com.
In the letter, Arnone comments on several key corporate and
operational accomplishments achieved by American CryoStem in the
past 12 months and on the Company's primary goals and objectives
for the coming year. In the letter, Arnone states:
"American CryoStem Corporation is a front runner in the rapidly
developing global cell therapy tissue processing and cellular
expansion markets. At the core of our business strategy and the
foundation of our Company is our state-of-art, FDA-registered
(FEI#3008307548), cGMP tissue processing laboratory located in
Burlington County, New Jersey. Our laboratory R&D efforts over
the last four years have produced significant intellectual property
surrounding our cellular processing platform and bio-materials for
which we currently have five U.S. patents pending and one patent
issued.The issued patent covers our cutting edge method to
formulate and manufacture 11 types of stem cell growth and
differentiation mediums used in research and cellular therapy. We
are in discussions with research universities to develop a unique
pipeline of proprietary products and services that we believe
target our proposed long term commercial growth strategy: to create
standardized tissue processing, clinical grade tissue samples, stem
cell samples and bio-materials for use in research and human
applications. With 2013 now behind us, I wanted to use this
opportunity to inform you on several material developments we
believe will positively impact our growth in 2014:
- Launch of our tissue storage service ATGRAFT™ and IRB approval
of our core processes;
- Status of our patented cell growth and differentiation media
ACSelerate™;
- Establishment of research collaborations with leading research
universities and institutions;
- Expansion of our Medical & Scientific Advisory Boards &
key personnel;
- Creation of international relationships for cosmetic and
regenerative medicine applications; and
- Engagement of an Investment Banking Firm."
To view the CEO letter in its entirety, please go to
http://www.americancryostem.com/american-cryostem-letter-to-shareholders/.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized
Medicine, American CryoStem is a developer, marketer and global
licensor of patented adipose tissue-based cellular technologies and
related proprietary services with a focus on clinical processing,
commercial bio-banking and application development for adipose
(fat) tissue and autologous adipose-derived regenerative cells
(ADRCs). The Company maintains a strategic portfolio of
intellectual property and patent applications that form its Adipose
Tissue Processing Platform, which supports and promotes a growing
pipeline of biologic products and processes, clinical services and
international licensing opportunities. Through its ACS
Laboratories division, the Company operates an FDA registered, cGMP
compliant human tissue processing, cryo-storage, cell culture and
differentiation media development facility in Mount Laurel, New
Jersey.
For more information, please visit
www.americancryostem.com and
www.acslaboratories.com.
Forward Looking Statements
This press release may contain forward-looking statements,
including information about management's view of American CryoStem
Corporation's ("the Company") future expectations, plans and
prospects. In particular, when used in the preceding
discussion, the words "believes," "expects," "intends," "plans,"
"anticipates," or "may," and similar conditional expressions are
intended to identify forward-looking statements. Any
statements made in this press release other than those of
historical fact, about an action, event or development, are
forward-looking statements. These statements involve known and
unknown risks, uncertainties and other factors, which may cause the
results of the Company, its subsidiaries and concepts to be
materially different than those expressed or implied in such
statements. Unknown or unpredictable factors also could have
material adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or
achievements. Accordingly, you should not place undue reliance
on these forward-looking statements. Finally, the Company
undertakes no obligation to update these statements after the date
of this release, except as required by law, and also takes no
obligation to update or correct information prepared by third
parties that are not paid for by American CryoStem Corporation.
CONTACT: Hanover|Elite
Kathy Addison, Chief Operating Officer
407-585-1080 or via email at CRYO@hanoverelite.com
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Jul 2024 to Aug 2024
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Aug 2023 to Aug 2024